Pharmaceutical

STAT+: Pharmalittle: Winners and losers from Medicare d...

On Tuesday, the U.S. government named 10 medicines that will be subject to Medic...

STAT+: Workforce, capacity constraints slow ramp-up of ...

Thousands of patients are stuck on waiting lists for the new Alzheimer's therapy...

Emotional dry cleaning: A writer helps doctors share th...

In virtual writing workshops, Laurel Braitman has created a place where health c...

STAT+: KRAS, the ideal cancer drug target that became ‘...

“This is the saga of the pharmaceutical industry. One or two drugs are approved ...

Opinion: How learning the truth about chaos theory has ...

A new understanding of the butterfly effect has changed how one inpatient child ...

Alvotech and Bioventure gain approval for Humira biosim...

Alvotech and Bioventure received the Egyptian Drug Authority's approval to produ...

Ipilimumab by Bristol-Myers Squibb for Metastatic Trans...

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently i...

FDA shuns Outlook Therapeutics with wet AMD drug BLA re...

Shares in the company tanked 80% following the FDA issued a CRL for its bevacizu...

Codagenix pursues RSV vaccine development amid unexpect...

Codagenix faces a late 2024 data readout following enrollment challenges in its ...

Roche wins first approval for subcutaneous Tecentriq

The subcutaneous Tecentriq has been approved in the UK for all indications that ...

Signal: PureHealth UK expansion shows continued focus o...

The $1.5bn deal is the largest the newly formed company have performed yet, but ...

FDA grants priority review for Zealand Pharma’s dasiglu...

The US FDA has granted priority review for Zealand Pharma’s dasiglucagon for hyp...

FibroGen’s pamrevlumab disappointing results marks seco...

The Phase III trial for FibroGen’s antibody candidate failed to meet its primary...

Biostax and Immgenuity to expedite HIV immunotherapies ...

Biostax and Immgenuity have entered into an agreement to expedite the developmen...

EC grants approval to Merck’s Keytruda for gastric cancer

The EC has granted approval for Merck’s Keytruda regimen for gastric or gastroes...

STAT+: Winners and losers from Medicare’s list of drugs...

Here's a look at winners and losers from Medicare’s newly released list of drugs...